title: Amitriptyline Usage Exacerbates the Immune Suppression Following Burn Injury.
abstract: Currently, over 10% of the US population is taking antidepressants. Numerous antidepressants such as amitriptyline are known to inhibit acid sphingomyelinase (Asm), an enzyme that is known to mediate leukocyte function and homeostasis. Severe burn injury can lead to an immunosuppressive state that is characterized by decreased leukocyte function and numbers as well as increased susceptibility to infection. Based upon the intersection of these facts, we hypothesized that amitriptyline-treated, scald-injured mice would have an altered immune response to injury as compared with untreated scald mice. Prior to burn, mice were pretreated with amitriptyline. Drug- or saline-treated mice were subjected full thickness dorsal scald- or sham-injury. Immune cells from spleen, thymus, and bone marrow were subsequently harvested and characterized. We first observed that amitriptyline prior to burn injury increased body mass loss and spleen contraction. Both amitriptylinetreatment and burn injury resulted in a 40% decrease of leukocyte Asm activity. Following scald injury, we demonstrate increased reduction of lymphocyte precursors in the bone marrow and thymus, as well as mature leukocytes in the spleen in mice that were treated with amitriptyline. We also demonstrate that amitriptyline treatment prior to injury reduced neutrophil accumulation following peptidoglycan stimulus in scald-injured mice. These data show that Asm alterations can play a significant role in mediating alterations to the immune system after injury. The data further suggest that those taking antidepressants may be at a higher risk for complications following burn injury.
authors.affiliation: *Division of Research, Department of Surgery, College of Medicine, University of Cincinnati, Cincinnati, Ohio †Department of Molecular Biology, University of Essen, Essen, Germany ‡Department of Research, Shriner's Hospital for Children, Cincinnati, Ohio.
authors.forename: Bobby L
authors.initials: BL
authors.lastname: Johnson
authors.forename: Teresa C
authors.initials: TC
authors.lastname: Rice
authors.forename: Brent T
authors.initials: BT
authors.lastname: Xia
authors.forename: Kirsten I
authors.initials: KI
authors.lastname: Boone
authors.forename: Ellis A
authors.initials: EA
authors.lastname: Green
authors.forename: Erich
authors.initials: E
authors.lastname: Gulbins
authors.forename: Charles C
authors.initials: CC
authors.lastname: Caldwell
mesh_terms: D000639:Amitriptyline / Q000627:therapeutic use*; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D015153:Blotting, Western; D002056:Burns / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D007165:Immunosuppression Therapy; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D020556:Neutrophil Infiltration / Q000187:drug effects; D013154:Spleen / Q000187:drug effects / Q000378:metabolism
chemical_list: D000929:Antidepressive Agents, Tricyclic; D018925:Chemokines; D016207:Cytokines; D000639:Amitriptyline